Nutrient supplementation approaches in the treatment of ADHD

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up: I. Psychiatric status. Arch. Gen. Psychiatry42(10), 937–947 (1985).
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry164(6), 942–948 (2007).
   PubMed Web of Science ®Google Scholar
• Almeida Montes LG, Hernandez Garcia AO, Ricardo-Garcell J. ADHD prevalence in adult outpatients with nonpsychotic psychiatric illnesses. J. Atten. Disord.11(2), 150–156 (2007).
   PubMedGoogle Scholar
• Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am. J. Psychiatry163(4), 716–723 (2006).
   PubMed Web of Science ®Google Scholar
• Rucklidge JJ. Gender differences in ADHD: implications for psychosocial treatments. Expert Rev. Neurother.8(4), 643–655 (2008).
   PubMedGoogle Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry56(12), 1073–1086 (1999).
   PubMed Web of Science ®Google Scholar
• Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (3rd Edition). Barkley RA (Ed.). The Guilford Press, NY, USA (2006).
   Google Scholar
• Spencer T, Biederman J, Wilens T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry57(5), 456–463 (2005).
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry59(9), 829–835 (2006).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Hammerness PG, Biederman J et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry66(2), 253–259 (2005).
   PubMed Web of Science ®Google Scholar
• Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J. Paediatr. Child Health41(1–2), 23–26 (2005).
   PubMed Web of Science ®Google Scholar
• Bussing R, Zima BT, Gary FA, Garvan CW. Use of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorder. Psychiatr. Serv.53(9), 1096–1102 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson K, Dowson C, Mangin D. Prevalence of complementary and alternative medicine use in Christchurch, New Zealand: children attending general practice versus paediatric outpatients. NZ J. Med.120(1251), 1–9 (2007).
   Google Scholar
• Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J. Dev. Behav. Pediatr.23(Suppl. 1), S37–S45 (2002).
   PubMed Web of Science ®Google Scholar
• Stubberfield TG, Wray TA, Parry TS. Utilization of alternative therapies in attention-deficit hyperactivity disorder. J. Paediatr. Child Health35, 450–453 (1999).
   PubMed Web of Science ®Google Scholar
• Munoz K, Krebs-Smith S, Ballard-Barbash R, Cleveland L. Food intakes of US children and adolescents compared with recommendations. Pediatrics100, 323–329 (1997).
   PubMed Web of Science ®Google Scholar
• Greenblatt J. Nutritional supplements in ADHD. J. Am. Acad. Child Adolesc. Psychiatry38(10), 1209–1210 (1999).
   PubMed Web of Science ®Google Scholar
• Haslam R. Is there a role for megavitamin therapy in the treatment of attention-deficit hyperactivity disorder? Adv. Neurol.58, 303–310 (1992).
   PubMedGoogle Scholar
• Baime MJ. Review: St. John’s wort, ginkgo, saw palmetto, and kava may be effective for some conditions. ACP J. Club,137(1), 25 (2002).
   PubMedGoogle Scholar
• Coleman M, Steinberg G, Tippett J et al. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate. Biol. Psychiatry14, 741–751 (1979).
   PubMed Web of Science ®Google Scholar
• Konofal E, Lecendreux M, Arnulf I, Mouren M-C. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch. Paediatr. Adolesc. Med.158(12), 1113–1115 (2004).
   PubMedGoogle Scholar
• Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention deficit hyperactivity disorder: a preliminary report. Neuropsychobiology35(4), 178–180 (1997).
   PubMed Web of Science ®Google Scholar
• Konofal E, Lecendreux M, Deron J et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr. Neurol.38(1), 20–26 (2008).
   PubMed Web of Science ®Google Scholar
• Kordas K, Stoltzfus RJ, Lapez P, Rico JA, Rosado JL. Iron and zinc supplementation does not improve parent or teacher ratings of behavior in first grade Mexican children exposed to lead. J. Pediatrics147(5), 632–639 (2005).
   PubMed Web of Science ®Google Scholar
• Starobrat-Hermelin B. [The effect of deficiency of selected bioelements on hyperactivity in children with certain specified mental disorders]. Ann. Acad. Med. Stetin.44, 297–314 (1998).
   PubMedGoogle Scholar
• Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes. Res.10(2), 143–148 (1997).
   PubMed Web of Science ®Google Scholar
• Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnes. Res.10(2), 149–156 (1997).
   PubMed Web of Science ®Google Scholar
• Arnold LE, Pinkham SM, Votolato N. Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder? J. Child Adolesc. Psychopharmacol.10(2), 111–117 (2000).
   PubMed Web of Science ®Google Scholar
• Yorbik O, Ozdag MF, Olgun A et al. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Progress in neuro-psychopharmacology Biol. Psychiatry32(3), 662–667 (2008).
   Web of Science ®Google Scholar
• Toren P, Eldar S, Sela B-A, Wolmer L, et al. Zinc deficiency in attention-deficit hyperactivity disorder. Biol. Psychiatry40(12), 1308–1310 (1996).
   PubMed Web of Science ®Google Scholar
• Arnold LE, Votolato NA, Kleykamp D et al. Does hair zinc predict amphetamine improvement of ADD/hyperactivity? Int. J. Neurosci.50(1–2), 103–107 (1990).
   PubMed Web of Science ®Google Scholar
• Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.15(4), 619–627 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold LE, Bozzolo H, Hollway J et al. Serum zinc correlates with parent- and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.15(4), 628–636 (2005).
   PubMed Web of Science ®Google Scholar
• Bilici M, Yildirim F, Kandil S et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry28(1), 181–190 (2004).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Mohammadi M-R, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry4, 9 (2004).
   PubMed Web of Science ®Google Scholar
• Wood DR, Reimherr FW, Wender PH. Treatment of attention deficit disorder with DL-phenylalanine. Psychiatry Res.16(1), 21–26 (1985).
   PubMed Web of Science ®Google Scholar
• Nemzer ED, Arnold LE, Votolato NA, McConnell H. Amino acid supplementation as therapy for attention deficit disorder. J. Am. Acad. Child Psychiatry25(4), 509–513 (1986).
   PubMedGoogle Scholar
• Reimherr FW, Wender PH, Wood DR, Ward M. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. Am. J. Psychiatry144(8), 1071–1073 (1987).
   PubMed Web of Science ®Google Scholar
• Shekim WO, Antun F, Hanna GL, McCracken JT et al.S-adenosyl-L-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol. Bull.26(2), 249–253 (1990).
   PubMedGoogle Scholar
• Arnold LE, Amato A, Bozzolo H et al. Acetyl-L-carnitine in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J. Child Adolesc. Psychopharmacol.17(6), 791–801 (2007).
   PubMed Web of Science ®Google Scholar
• Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot. Essent. Fatty Acids67(1), 33–38 (2002).
   PubMed Web of Science ®Google Scholar
• Torrioli MG, Vernacotola S, Peruzzi L et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am. J. Med. Genet. A.146(7), 803–812 (2008).
   Google Scholar
• Sadiq AJ. Attention-deficit/hyperactivity disorder and integrative approaches. Psychiatr. Ann.37(9), 630–638 (2007).
   Web of Science ®Google Scholar
• Stevens L, Zhang W, Peck L et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids38(10), 1007–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med. Hypotheses7, 673–679 (1981).
   PubMed Web of Science ®Google Scholar
• Arnold LE, Kleykamp D, Votolato N et al. Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol.4(3), 171–182 (1994).
   Web of Science ®Google Scholar
• Brookes KJ, Chen W, Xu X, Taylor E, Asherson P. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol. Psychiatry60(10), 1053–1061 (2006).
   PubMed Web of Science ®Google Scholar
• Antalis CJ, Stevens LJ, Campbell M et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot. Essent. Fatty Acids75(4–5), 299–308 (2006).
   PubMed Web of Science ®Google Scholar
• Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis.6, 21 (2007).
   PubMed Web of Science ®Google Scholar
• Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int. Rev. Psychiatry18(2), 155–172 (2006).
   PubMed Web of Science ®Google Scholar
• Voigt RG, Llorente AM, Jensen CL et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatrics139(2), 189–196 (2001).
   PubMed Web of Science ®Google Scholar
• Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder – a placebo-controlled double-blind study. Eur. J. Clin. Nutr.58(3), 467–473 (2004).
   PubMed Web of Science ®Google Scholar
• Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J. Dev. Behav. Pediatr.28(2), 82–91 (2007).
   PubMed Web of Science ®Google Scholar
• Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot. Essent. Fatty Acids78(4–5), 311–326 (2008).
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Puri BK. A randomized double-blind, placebo controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharmacol. Biol. Psychiatry26, 233–239 (2002).
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Montgomery P. The Oxford–Durham study: a randomized controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics115(5), 1360–1366 (2005).
   PubMed Web of Science ®Google Scholar
• Busch B. Polyunsaturated fatty acid supplementation for ADHD? Fishy, fascinating, and far from clear. J. Dev. Behav. Pediatr.28(2), 139–144 (2007).
   PubMed Web of Science ®Google Scholar
• Clayton EH, Hanstock TL, Garg ML, Hazell PL. Long chain omega-3 polyunsaturated fatty acids in the treatment of psychiatric illnesses in children and adolescents. Acta Neuropsychiatrica19, 92–103 (2007).
   PubMed Web of Science ®Google Scholar
• Bussmann RW, Sharon D. Traditional medicinal plant use in Northern Peru: tracking two thousand years of healing culture. J. Ethnobiol. Ethnomed.2, 47 (2006).
   PubMed Web of Science ®Google Scholar
• Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int. J. Clin. Pharmacol. Ther.40(4), 158–168 (2002).
   PubMed Web of Science ®Google Scholar
• Zametkin AJ, Nordahl TE, Gross M et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N. Engl. J. Med.323(20), 1361–1366 (1990).
   PubMed Web of Science ®Google Scholar
• Schweitzer JB, Lee DO, Hanford RB et al. A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology28(5), 967–973 (2003).
   PubMed Web of Science ®Google Scholar
• Dvorakova M, Jezova D, Blazicek P et al. Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): modulation by a polyphenolic extract from pine bark (Pycnogenol). Nutr. Neurosci.10(3–4), 151–157 (2007).
   PubMed Web of Science ®Google Scholar
• Trebaticka J, Kopasova S, Hradecna Z et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur. Child Adolesc. Psychiatry15(6), 329–335 (2006).
   PubMed Web of Science ®Google Scholar
• Chovanova Z, Muchova J, Sivonova M et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radic. Res.40(9), 1003–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Hannah G, Ornitz E, Hariharan M. Urinary catecholamine excretion and behavioral differences in ADHD and normal boys. J. Child Adolesc. Psychopharmacol.6(1), 63–73 (1996).
   PubMed Web of Science ®Google Scholar
• Pliszka S, Maas J, Javors M, Rogeness G, Baker J. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety. J. Am. Acad. Child Adolesc. Psychiatry33(8), 1165–1173 (1994).
   PubMed Web of Science ®Google Scholar
• Dvorakova M, Sivonova M, Trebaticka J et al. The effect of polyphenolic extract from pine bark, Pycnogenol on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD). Redox Rep.11(4), 163–172 (2006).
   PubMed Web of Science ®Google Scholar
• Tenenbaum S, Paull JC, Sparrow EP, Dodd DK, Green L. An experimental comparison of Pycnogenol® and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). J. Atten. Disord.6(2), 49–60 (2002).
   PubMedGoogle Scholar
• Itoh T, Zang YF, Murai S, Saito H. Effects of Panax ginseng root on the vertical and horizontal motor activities and on brain monoamine-related substances in mice. Planta Med.55(5), 429–433 (1989).
   PubMed Web of Science ®Google Scholar
• Ramassamy C, Naudin B, Christen Y, Clostre F, Costentin J. Prevention by Ginkgo biloba extract (EGb 761) and trolox C of the decrease in synaptosomal dopamine or serotonin uptake following incubation. Biochem. Pharmacol.44(12), 2395–2401 (1992).
   PubMed Web of Science ®Google Scholar
• Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol. Bull.121(1), 65–94 (1997).
   PubMed Web of Science ®Google Scholar
• Lyon MR, Cline JC, Totosy de Zepetnek J et al. Effect of the herbal extract combination Panax quinquefolium and Ginko biloba on attention-deficit hyperactivity disorder: a pilot study. J. Psychiatry Neurosci.26(3), 221–228 (2001).
   PubMed Web of Science ®Google Scholar
• Weber W, Stoep AV, McCarty RL et al.Hypericum perforatum (St John’s wort) for attention-deficit/hyperactivity disorder in children and adolescents. JAMA299(22), 2633–2641 (2008).
   PubMed Web of Science ®Google Scholar
• Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res.816(2), 358–363 (1999).
   PubMed Web of Science ®Google Scholar
• Muller WE, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry30(Suppl. 2), 102–107 (1997).
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child Adolesc. Psychiatry41(7), 776–784 (2002).
   PubMed Web of Science ®Google Scholar
• Gesch B, Hammond S, Hampson S, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Br. J. Psychiatry181, 22–28 (2002).
   PubMed Web of Science ®Google Scholar
• Schoenthaler SJ, Bier ID. The effect of vitamin-mineral supplementation on juvenile delinquency among American schoolchildren: a randomized, double-blind placebo-controlled trial. J. Altern. Complement. Med.6(1), 7–17 (2000).
   PubMed Web of Science ®Google Scholar
• Schoenthaler SJ, Amos SP, Eysenck HJ, Peritz E et al. Controlled trial of vitamin-mineral supplementation: effects on intelligence and performance. Pers. Individ. Dif.12(4), 351–362 (1991).
   Web of Science ®Google Scholar
• Mousain-Bosc M, Roche M, Polge A et al. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magnes. Res.19(1), 46–52 (2006).
   PubMed Web of Science ®Google Scholar
• Joshi K, Lad S, Kale M et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukot. Essent. Fatty Acids74(1), 17–21 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan BJ, Fisher JE, Crawford SG, Field CJ, Kolb B. Improved mood and behavior during treatment with a mineral-vitamin supplement: an open-label case series of children. J. Child Adolesc. Psychopharmacol.14(1), 115–122 (2004).
   PubMed Web of Science ®Google Scholar
• Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilising effects? J. Clin. Psychiatry62(12), 933–935 (2001).
   PubMed Web of Science ®Google Scholar
• Rucklidge J, Taylor M, Whitehead K, Johnstone J. Can minerals and vitamins be used to treat mental illness? Evidence from an open label trial of adults with ADHD and mood instability. Presented at: New Zealand College of Clinical Psychologists Annual Conference. Dunedin, NZ, 31 January–1 February 2009.
   Google Scholar
• Harding KL, Judah RD, Gant C. Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. J. Clin. Ther.8(3), 319–330 (2003).
   Google Scholar
• Patel K, Curtis LT. Comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. J. Altern. Complement. Med.13(10), 1091–1097 (2007).
   PubMed Web of Science ®Google Scholar
• Kaplan BJ, Crawford SG, Field CJ, Simpson JS. Vitamins, minerals, and mood. Psychol. Bull.133(5), 747–760 (2007).
   PubMed Web of Science ®Google Scholar
• Ames BN, Elson-Schwab I, Silver E. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am. J. Clin. Nutr.75, 616–658 (2002).
   PubMed Web of Science ®Google Scholar
• Nigg JT. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol. Psychiatry57(11), 1424–1435 (2005).
   PubMed Web of Science ®Google Scholar